Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 339

1.

Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center.

Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF.

Eur J Cancer. 2019 May;112:83-93. doi: 10.1016/j.ejca.2019.02.007. Epub 2019 Apr 2.

PMID:
30951926
2.

Prospective Clinical Sequencing of Adult Glioma.

Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF.

Mol Cancer Ther. 2019 May;18(5):991-1000. doi: 10.1158/1535-7163.MCT-18-1122. Epub 2019 Mar 29.

PMID:
30926639
3.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

4.

Health professionals' involvement and information provision in genetic counseling following prenatal diagnosis of sex chromosome aneuploidy in Hong Kong.

So PL, Cheng YKY, Cheuk KY, Chiu WK, Mak SL, Mok SL, Lo TK, Yung WK, Lo FM, Chung BHY, Kan ASY, Lee CP, Tang MHY.

Int J Gynaecol Obstet. 2019 Mar;144(3):314-316. doi: 10.1002/ijgo.12737. Epub 2018 Dec 19.

PMID:
30516269
5.

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J.

J Clin Oncol. 2018 May 10;36(14):1419-1427. doi: 10.1200/JCO.2017.75.8219. Epub 2018 Feb 12.

6.

NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Curran WJ Jr.

J Neurooncol. 2018 Mar;137(1):39-47. doi: 10.1007/s11060-017-2558-x. Epub 2018 Feb 5.

7.

Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.

Wu S, Wang S, Gao F, Li L, Zheng S, Yung WKA, Koul D.

Neuro Oncol. 2018 Jan 10;20(1):78-91. doi: 10.1093/neuonc/nox128.

8.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

9.

Parental decisions following prenatal diagnosis of sex chromosome aneuploidy in Hong Kong.

So PL, Cheng KYY, Cheuk KY, Chiu WK, Mak SL, Mok SL, Lo TK, Yung WK, Lo FM, Chung HYB, Kan SYA, Lee CP, Tang HYM.

J Obstet Gynaecol Res. 2017 Dec;43(12):1821-1829. doi: 10.1111/jog.13451. Epub 2017 Sep 11.

PMID:
28892214
10.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

11.

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.

Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA.

Oncotarget. 2017 Mar 28;8(13):21741-21753. doi: 10.18632/oncotarget.15566.

12.

Additive and Photochemical Manufacturing of Copper.

Yung WK, Sun B, Meng Z, Huang J, Jin Y, Choy HS, Cai Z, Li G, Ho CL, Yang J, Wong WY.

Sci Rep. 2016 Dec 21;6:39584. doi: 10.1038/srep39584.

13.

Photochemical Copper Coating on 3D Printed Thermoplastics.

Yung WK, Sun B, Huang J, Jin Y, Meng Z, Choy HS, Cai Z, Li G, Ho CL, Yang J, Wong WY.

Sci Rep. 2016 Aug 9;6:31188. doi: 10.1038/srep31188.

14.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

15.

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.

Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF.

J Neurooncol. 2016 Sep;129(3):487-494. doi: 10.1007/s11060-016-2195-9. Epub 2016 Jul 12.

16.

MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK.

Mol Cancer Ther. 2016 Jul;15(7):1656-68. doi: 10.1158/1535-7163.MCT-15-0857. Epub 2016 Apr 22.

17.

Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.

Cortes-Santiago N, Hossain MB, Gabrusiewicz K, Fan X, Gumin J, Marini FC, Alonso MM, Lang F, Yung WK, Fueyo J, Gomez-Manzano C.

Oncotarget. 2016 Mar 29;7(13):16146-57. doi: 10.18632/oncotarget.7550.

18.

A brief group intervention using a cognitive-behavioural approach to reduce postnatal depressive symptoms: a randomised controlled trial.

Leung SS, Lee AM, Wong DF, Wong CM, Leung KY, Chiang VC, Yung WK, Chan SW, Chung KF.

Hong Kong Med J. 2016 Feb;22 Suppl 2:S4-8. No abstract available.

19.

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG.

Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028.

20.

Is intrapartum translabial ultrasound examination painless?

Chan YT, Ng KS, Yung WK, Lo TK, Lau WL, Leung WC.

J Matern Fetal Neonatal Med. 2016 Oct;29(20):3276-80. doi: 10.3109/14767058.2015.1123241. Epub 2015 Dec 23.

PMID:
26699380
21.

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR; Brain Tumor Trials Collaborative.

J Neurooncol. 2016 Jan;126(1):185-192. doi: 10.1007/s11060-015-1958-z.

22.

Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.

Liu Q, Liu Y, Li W, Wang X, Sawaya R, Lang FF, Yung WK, Chen K, Fuller GN, Zhang W.

Acta Neuropathol. 2015 Oct;130(4):587-97. doi: 10.1007/s00401-015-1470-8. Epub 2015 Sep 1.

23.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee.

Neuro Oncol. 2015 Sep;17(9):1188-98. doi: 10.1093/neuonc/nov095. Epub 2015 Aug 5. Review.

24.

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ.

Clin Cancer Res. 2015 Oct 15;21(20):4630-41. doi: 10.1158/1078-0432.CCR-14-3195. Epub 2015 Jun 23.

25.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J.

N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

26.

Twin pregnancy outcomes after increasing rate of vaginal twin delivery: retrospective cohort study in a Hong Kong regional obstetric unit.

Tang HT, Liu AL, Chan SY, Lau CH, Yung WK, Lau WL, Leung WC.

J Matern Fetal Neonatal Med. 2016;29(7):1094-100. doi: 10.3109/14767058.2015.1035640. Epub 2015 Apr 20.

PMID:
25893547
27.

Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.

Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3421-6. doi: 10.1073/pnas.1414573112. Epub 2015 Mar 3.

28.

Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis.

Pachella LA, Kamiya-Matsuoka C, Lee EL, Olar A, Yung WK.

J Clin Neurosci. 2015 Mar;22(3):605-7. doi: 10.1016/j.jocn.2014.09.006. Epub 2014 Oct 31.

29.

Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells.

Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H.

Cancer Res. 2014 Nov 15;74(22):6731-2. doi: 10.1158/0008-5472.CAN-14-2966. No abstract available.

30.

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii36-47. doi: 10.1093/neuonc/nou226.

31.

Imaging endpoints in brain tumor clinical trials: proceedings of the January 30, 2014 Workshop. Introduction.

Yung WK.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii1. doi: 10.1093/neuonc/nou291. Epub 2014 Oct 13. No abstract available.

32.

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative.

Neuro Oncol. 2015 Feb;17(2):266-73. doi: 10.1093/neuonc/nou155. Epub 2014 Sep 19.

33.

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY.

Neuro Oncol. 2015 Feb;17(2):180-8. doi: 10.1093/neuonc/nou154. Epub 2014 Aug 26. Review.

34.

Relationship between intrapartum transperineal ultrasound measurement of angle of progression and head-perineum distance with correlation to conventional clinical parameters of labor progress and time to delivery.

Chan YT, Ng VK, Yung WK, Lo TK, Leung WC, Lau WL.

J Matern Fetal Neonatal Med. 2015 Aug;28(12):1476-81. doi: 10.3109/14767058.2014.958459. Epub 2014 Sep 29.

PMID:
25163523
35.

PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis.

Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Yung WKA, Lu Z.

Cell. 2014 Aug 28;158(5):1210. doi: 10.1016/j.cell.2014.08.003. Epub 2014 Aug 28. No abstract available.

36.

Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies.

Peng Z, Maxwell D, Sun D, Ying Y, Schuber PT Jr, Bhanu Prasad BA, Gelovani J, Yung WK, Bornmann WG.

Tetrahedron. 2014 Jan 28;70(4):984-990.

37.

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.

Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J.

PLoS One. 2014 May 14;9(5):e97407. doi: 10.1371/journal.pone.0097407. eCollection 2014.

38.

Social obstetrics: non-local expectant mothers admitted through accident and emergency department in a public hospital in Hong Kong.

Yung WK, Hui W, Chan YT, Lo TK, Tai SM, Sing C, Lam YY, Lo CM, Lau WL, Leung WC.

Hong Kong Med J. 2014 Jun;20(3):213-21. doi: 10.12809/hkmj134181. Epub 2014 May 9.

39.

Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF.

J Neurooncol. 2014 Aug;119(1):135-40. doi: 10.1007/s11060-014-1460-z. Epub 2014 May 7.

40.

Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.

Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q.

Cancer Immunol Res. 2014 Apr;2(4):371-9. doi: 10.1158/2326-6066.CIR-13-0088. Epub 2013 Nov 25.

41.

Rebound increase in vaginal delivery for twins in a regional obstetric unit in Hong Kong.

Tang HT, Liu AL, Yung WK, Lo TK, Lau WL, Leung WC.

Int J Gynaecol Obstet. 2014 Jul;126(1):96-7. doi: 10.1016/j.ijgo.2014.01.009. Epub 2014 Mar 19. No abstract available.

PMID:
24721616
42.

Molecular subtypes of glioblastoma are relevant to lower grade glioma.

Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS.

PLoS One. 2014 Mar 10;9(3):e91216. doi: 10.1371/journal.pone.0091216. eCollection 2014.

43.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

44.

The somatic genomic landscape of glioblastoma.

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network.

Cell. 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034. Erratum in: Cell. 2014 Apr 24;157(3):753.

45.

Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers.

Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K, Yung WK, Weinstein JN, Tan M, Yao J.

Oncotarget. 2014 Sep 30;5(18):8202-10.

46.

New Neuro-Oncology Practice journal to launch in 2014.

Chang S, Yung WK.

Neuro Oncol. 2013 Oct;15(10):1277. doi: 10.1093/neuonc/not160. No abstract available.

47.

A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.

Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D.

Stem Cells. 2014 Jan;32(1):301-12. doi: 10.1002/stem.1528.

48.

Higher impact, wider influence.

Yung WK.

Neuro Oncol. 2013 Sep;15(9):1113. doi: 10.1093/neuonc/not135. No abstract available.

49.

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Zhang C, Moore LM, Li X, Yung WK, Zhang W.

Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Review.

50.

Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825.

Weller M, Yung WK.

Neuro Oncol. 2013 Aug;15(8):971. doi: 10.1093/neuonc/not106. No abstract available.

Supplemental Content

Support Center